A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial, Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years and Older Who Received One Dose of 23vPS At Least 5 Years Prior to Study Enrollment.

Trial Profile

A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial, Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years and Older Who Received One Dose of 23vPS At Least 5 Years Prior to Study Enrollment.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2013

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 10 May 2011 Primary endpoint 'Antibody-levels' has been met.
    • 22 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 16 Apr 2010 Trial locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top